Alpha Cognition Inc. (NASDAQ: ACOG) announced that the European Patent Office has granted a patent covering a crystalline solid form of benzgalantamine, the active ingredient in its Alzheimer's drug Zunveyl, for the treatment of mild-to-moderate Alzheimer's disease.

The patent includes claims directed to the crystalline solid form, related pharmaceutical compositions, preparations, methods of manufacture, and medical-use claims. The company said the grant may provide patent protection for benzgalantamine through 2042, subject to applicable patent requirements.

The patent may be validated in European Patent Convention member states, covering both European Union and non-EU jurisdictions such as Switzerland and the United Kingdom.

"This European patent grant is another important step in our strategy to build broad intellectual property protection around benzgalantamine and Zunveyl as a differentiated treatment option for patients with mild-to-moderate Alzheimer's disease," said Michael McFadden, Chief Executive Officer of Alpha Cognition.

Zunveyl is FDA-approved as an acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. The information in this article is based on a press release from Alpha Cognition.